Company / R&D Expense
NovaBay Pharmaceuticals, Inc. R&D Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$42.0K
FY2024
5-year range
$34.0K / $285.0K
FY2020-FY2024
Trend
+23.5%
vs FY2023
Sector context
#209 of 209
Health Care
What the data says
Among 209 Health Care companies, NovaBay Pharmaceuticals, Inc. is in the bottom 0% for r&d expense. R&D Expense has fluctuated over the past 10 years, ranging from $34,000 in FY2023 to $6M in FY2015.
Based on SEC 10-K filings.
$42,000 in FY2024 with a 5-year CAGR of -25.6%.
Declined from $174,000 to $42,000 over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -1.5%
- 5-Year CAGR
- -25.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 0% in Health CareTop 100% of 209This company $42.0K Sector average $647.6M
▼
-100.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -25.6%, indicating a declining trend.
- In FY2024, r&d expense increased 23.5% year-over-year.
- Ranks #209 out of 209 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $42.0K | +23.5% |
| FY2023 | $34.0K | -80.5% |
| FY2022 | $174.0K | +295.5% |
| FY2021 | $44.0K | -84.6% |
| FY2020 | $285.0K | +54.9% |
| FY2019 | $184.0K | -29.0% |
| FY2018 | $259.0K | -36.8% |
| FY2017 | $410.0K | -70.1% |
| FY2016 | $1.4M | -76.1% |
| FY2015 | $5.7M | -39.6% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026